In advanced non-small cell lung cancer (aNSCLC), patients with NLR>5, combined with high PD-L1 expression levels (>80%), showed favorable outcome following first-line pembrolizumab monotherapy 87. The gene discussed is CD274; the disease is non-small cell lung carcinoma.